Akèy › Kansè nan tete › Connecticut › Bridgeport
Etid klinik pou Kansè nan tete nan Bridgeport, CT
21 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Bridgeport (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Stony Brook University Medical Center, Stony Brook · 18 mi lwen
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Ap rekriteFaz 3
- Stony Brook University-Cancer Center ( Site 0034), Stony Brook · 18 mi lwen
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Ap rekriteFaz 3
- Research Site, Stony Brook · 18 mi lwen
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Ap rekriteFaz 3
- Smilow Cancer Hospital Care Center - Trumbull, Trumbull · 4 mi lwen
- Smilow Cancer Hospital Care Center - Fairfield, Fairfield · 5 mi lwen
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Ap rekrite
- Stony Brook Cancer Center, Stony Brook · 18 mi lwen
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Ap rekriteFaz 1/2
- Stony Brook University Hospital, Stony Brook · 18 mi lwen
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Ap rekriteFaz 3
- Stony Brook University Medical Center, Stony Brook · 18 mi lwen
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- Stony Brook University Cancer Center, Stony Brook · 18 mi lwen
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Ap rekriteFaz 3
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Port Jefferson Station2), Port Jefferson Station · 19 mi lwen
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C.(Port Jefferson Station1), Port Jefferson Station · 19 mi lwen
- New York Cancers & Blood Specialists, Port Jefferson Station · 19 mi lwen
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Hartford HealthCare - Saint Vincent's Medical Center, Bridgeport
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull · 4 mi lwen
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield · 5 mi lwen
- ak 1 plis
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Ap rekriteFaz 2
- Stony Brook Cancer Center, Stony Brook · 18 mi lwen
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Ap rekriteFaz 2
- Smilow Cancer Hospital Care center at Trumbull, Trumbull · 4 mi lwen
- Smilow Cancer Hospital Care center at Fairfield, Fairfield · 5 mi lwen
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Ap rekriteFaz 1
- New York Cancer and Blood Specialists, Port Jefferson Station · 19 mi lwen
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Ap rekriteFaz 3
- Stony Brook University Cancer Center, Stony Brook · 18 mi lwen
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Ap rekriteFaz 3
- Smilow Cancer Hospital - Fairfield, Fairfield · 5 mi lwen
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull · 4 mi lwen
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield · 5 mi lwen
- Stony Brook University Medical Center, Stony Brook · 18 mi lwen
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Ap rekriteEtid obsèvasyon
- Stony Brook Medicine, Stony Brook · 18 mi lwen
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
Ap rekriteFaz 1 bonè
- Stony Brook Breast Center, Stony Brook · 18 mi lwen
Definitive Radiation Therapy for Inoperable Breast Cancer
Ap rekrite
- Stony Brook University Cancer Center, Stony Brook · 18 mi lwen
Definitive Radiation for High-Risk Spine Metastases
Ap rekriteFaz 2
- Stony Brook University Hospital, Stony Brook · 18 mi lwen
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Ap rekriteEtid obsèvasyon
- Stony Brook University Cancer Center, Stony Brook · 18 mi lwen
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Bridgeport
- Kansè Poumon ki pa ti selil14 etid
- Kansè poumon13 etid
- Leksemi mieloïd egi12 etid
- Maladi kadyovaskilè9 etid
- Kansè (tout kalite)8 etid
- Karsinòm selil skuamèz tèt ak kou8 etid
- Kansè Metastatik7 etid
- Ensifizyans kadyak7 etid
- Aneurism sèvo6 etid
- Myelom Miltip6 etid
- Kansè pwostat6 etid
- Kansè ovè5 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.